Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01142193 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures
A Phase 3 study of Epilepsy, sponsored by Upsher-Smith Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 249
- Enrollment target
- 20
- Study locations
NCT01142193: Completed Phase 3 study of Epilepsy, sponsored by Upsher-Smith Laboratories.
NCT01142193 is a Phase 3 study of Epilepsy that has completed, run by Upsher-Smith Laboratories. The registered enrollment target is 249 participants, below the 951-participant average among 160 other Epilepsy trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01142193, a Phase 3 study of Epilepsy, has completed, sponsored by Upsher-Smith Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 249 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to examine the safety and effectiveness of USL255 as adjunctive therapy in patients with refractory partial onset-seizures.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG USL255
Study Locations (20)
Florida
- - Gainesville
- - Gulf Breeze
- - Jacksonville
- - Pensacola
- - Port Charlotte
Missouri
- - Chesterfield
- - St Louis
Texas
- - Dallas
- - Temple
Arizona
- - Phoenix
California
- - Ventura
Idaho
- - Boise
Kentucky
- - Lexington
Maryland
- - Waldorf
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-01 |
| Phase | Phase 3 |
What the finished NCT01142193 record still lists
NCT01142193 is an interventional study that assigns participants to a tested intervention. The registered 249 participants enrollment target is mid-sized for trials with a published cap, below the 951-participant average among 160 other Epilepsy trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01142193 names 20 study sites across 14 states, led by Florida, Missouri, Texas.
Frequently Asked Questions
What is clinical trial NCT01142193 about?
NCT01142193 is a clinical study titled "Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures". The purpose of this study is to examine the safety and effectiveness of USL255 as adjunctive therapy in patients with refractory partial onset-seizures.
What is the current status of trial NCT01142193?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 249 participants. The study started on 2010-05. Estimated completion is 2013-01.
What conditions does trial NCT01142193 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT01142193?
The interventions under investigation include: Placebo (DRUG), USL255 (DRUG).
Who is sponsoring clinical trial NCT01142193?
This trial is sponsored by Upsher-Smith Laboratories, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01142193 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Idaho, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01142193's enrollment target sits among peer trials
249 25th of 160 higher than 136 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
RECRUITING · Phase 3
-
Lemborexant Treatment of Insomnia Linked to Epilepsy
RECRUITING · Phase 3
-
RNS System NAUTILUS Study
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
COMPLETED · Phase 3
-
Clobazam in Patients With Lennox-Gastaut Syndrome
COMPLETED · Phase 3
-
Pediatric Epilepsy Study
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04628767 · 249 participants · Phase 2
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
- NCT05834907 · 249 participants · NA
Hands and Hearts Together
- NCT06067555 · 249 participants · Early Phase 1
Intradermal Influenza Vaccination
- NCT06588478 · 249 participants · Phase 2
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia